van Steenoven, Inger

Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach

van Steenoven, I., Koel-Simmelink, M. J. A., Vergouw, L. J. M., Tijms, B. M., Piersma, S. R., Pham, T. V., Bridel, C., Ferri, G.-L., Cocco, C., Noli, B., et al. (2020) · Molecular Neurodegeneration

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 83

Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF

Boiten, W., van Steenoven, I., Xiao, M.-F., Worley, P., Noli, B., Cocco, C., Ferri, G.-L., Lemstra, A., & Teunissen, C. (2020) · Cells

Dementia and Cognitive Impairment ResearchParkinson's Disease Mechanisms and Treatments

Cited by 42

Spectrum of Lewy body dementias: relationship of Parkinson’s disease dementia to dementia with Lewy bodies

Ballard, C., Garcia-Ptacek, S., van Steenoven, I., & Aarsland, D. (2015) · Cognitive Impairment and Dementia in Parkinson's Disease

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 5